Dr. David Y. Liu has over 23 years of Biotechnology industry experience in addition to 10 years of postgraduate academic research. Most recently he has spent more than 7 years at FibroGen Inc as Vice President of Research,   member of the Executive Staff and a Corporate Officer with responsibility for all therapeutic research and drug discovery at FibroGen. From 1992 - 2002, he worked at Scios Inc (since acquired by Johnson & Johnson) as Director of Inflammation Research and member of the Senior R&D staff. Dr. Liu's experience in the Biotechnology industry began in California at Cetus Corporation (since acquired by Chiron and now Novartis) and COR Therapeutics (since acquired by Millenium and now Takeda). Dr. Liu was a NIH postdoctoral fellow in the Department of Rheumatology at the Brigham and Women's Hospital, Harvard Medical School which was followed by promotions to Instructor and Assistant Professor in the Department of Medicine, Harvard Medical School, Boston, MA. He has been honored with several awards, such as the Young Investigator Award, Reticuloendonthelial Society. Dr. Liu graduated from the University of Chicago with a BS degree in Chemistry and earned his PhD degree in Microbiology and Immunology from Michigan State University. In total, Dr. Liu has published over 50 articles, filed 30 patent applications and been closely involved in filing 17 INDs and NDAs for several first-in-class chemical and biologic drugs in more than 10 clinical indications.

Therapeutic research and drug discovery